Dr Reddy’s Moves Ahead With Global Rituximab Filings
US FDA, EMA And MHRA Accept Firm’s Rituxan/MabThera Biosimilar Rival For Review
Dr Reddy’s has celebrated a “milestone” for its biosimilars business after disclosing that multiple regulators in Europe and the US have accepted its rituximab filings for review.
You may also be interested in...
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
Whether in the competitive world of US generics, the growing global biosimilars arena, or promising new geographical markets, Dr Reddy’s is seeking to capitalize on its strengths to remain competitive while also pushing forward with ESG goals, CEO Erez Israeli tells Generics Bulletin.